Drug Trial Radar · NCT07876817
A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 20, 2026
Primary completion
Jan 31, 2029
Study completion Jan 31, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 4, Single Arm Study To Assess The Safety and tolerability of Perioperative Durvalumab in Combination with Neoadjuvant Gemcitabine Plus Cisplatin Treatment Followed by radical cystectomy and Durvalumab alone as Treatment in Indian Patients with Muscle-Invasive Bladder Cancer. It is to be conducted in compliance with a condition of approval specified by Health Authority of India following the addition of this indication to the approved prescribing information. A phase IV clinical trial to Asses the safety profile of this regimen in patients from India and subsequently, any regulatory action resulting from the review should be complied.
Conditions
- Muscle-Invasive Bladder Cancer (MIBC)
Interventions
DurvalumabDrug
Solution for IV infusion, 1500 mg/vial. Administered at 1500 mg IV every 3 weeks during the neoadjuvant phase and every 4 weeks during the adjuvant phase.
GemcitabineDrug
Solution for IV infusion. Administered at 1000 mg/m² on Day 1 and Day 8 of each 21-day neoadjuvant cycle.
CisplatinDrug
Solution for IV infusion. Administered at 70 mg/m² on Day 1 of each 21-day neoadjuvant cycle. A split dose of 35 mg/m² on Days 1 and 8 may be used for patients with borderline renal function.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects experiencing adverse events (AEs)Time frame: Throughout the study, up to approximately 66 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.